Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What are the Key Projections for the CAGR of the Protein Degradation Therapy Market From 2025 to 2034?

The market size for protein degradation therapy has witnessed noteworthy growth in the recent past. The market is projected to expand from $1.16 billion in 2024 to $1.25 billion in 2025, boasting a compound annual growth rate (CAGR) of 8.2%. This significant increase during the historic period can be traced back to the mounting prevalence of neurodegenerative diseases, enhanced success rates of targeted therapies, augmented investment in biotech breakthroughs, a surging need for individualized medicine, and the increasing inability of traditional therapies to effectively treat certain diseases.

Anticipations are strong for significant expansion in the protein degradation therapy market over the coming years. Its value is projected to reach $1.7 billion in 2029, representing a compound annual growth rate (CAGR) of 7.9%. The escalation during the prediction period can be associated with the increasing cases of chronic illnesses, more significant investment in biotech research, an upsurge in the demand for targeted therapies, the enlargement of clinical trials, and an encouraging regulatory environment. Some of the prominent trends expected during this period encompass the evolution of next-generation PROTACs, the incorporation of artificial intelligence and machine learning, the introduction of combination therapies, the progression of personalized protein degradation therapies, and improvements in oral formulations and drug delivery systems.

What Are the Primary Drivers Supporting the Growth of the Protein Degradation Therapy Market?

The escalating prevalence of cancer is predicted to fuel the expansion of the protein degradation therapy market. Cancer encompasses a variety of ailments characterized by the unregulated growth and spread of abnormal cells. Cancer incidents are primarily on the rise due to several factors, among which the ageing population plays a crucial role. Other lifestyle factors like smoking, unhealthy dieting, physical inactivity, and growing rates of obesity have escalated the risk of various cancers. Protein degradation therapy is vital in treating cancer because it targets and eliminates certain proteins that promote cancer growth and proved resistant to traditional treatments. As per the World Health Organization’s report in February 2024, there would be over 35 million new cancer cases in 2050, indicating a 77% surge from the projected 20 million cases in 2022. Furthermore, countries with a high Human Development Index (HDI) are expected to see the biggest rise in absolute numbers, predicting an extra 4.8 million new cases in 2050 in comparison to 2022. Hence, the escalating prevalence of cancer is stimulating the expansion of the protein degradation therapy market.

Explore Comprehensive Insights Into The Global Protein Degradation Therapy Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20603&type=smp

What Are the Key Industry Players Leading the Charge in the Protein Degradation Therapy Market’s Growth?

Major companies operating in the protein degradation therapy market are:

• Relay Therapeutics

• Arvinas Holding Company LLC

• Kymera Therapeutics

• Nurix Therapeutics

• Vividion Therapeutics

How Are Market Trends and Shifts Impacting the Growth Trajectory of the Protein Degradation Therapy Market?

In an effort to develop novel treatments, major firms in the protein degradation therapy market are strategically partnering up. These collaborations allow the companies to share resources, tap into each other’s unique expertise, and expedite the identification and creation of new medication candidates that focus on proteins that cause disease. The goal of these strategic collaborations is to harness each other’s strong suits, accrue shared benefits, and achieve joint success. For example, in June 2022, science and technology firm Merck KGaA from Germany formed a substantial multi-year research alliance and licensing deal with Austria’s Proxygen, a biotech firm, for the development of molecular glue degraders. This deal, estimated at approximately $2.55 billion, comprises an initial payment and potential milestone-based payments contingent on achieving predefined research, development, and business targets. The alliance looks to benefit from Proxygen’s competencies in molecular glue degraders, aimed at selectively eliminating harmful proteins through reprogramming of cellular mechanisms. This innovative method targets proteins typically deemed “undruggable” by standard approaches, thereby exploring new potential paths for therapeutic innovation.

Get Instant Access to the Global Protein Degradation Therapy Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/protein-degradation-therapy-global-market-report

Which Growth-Oriented Segments of the Protein Degradation Therapy Market Are Leading the Industry’s Development?

The protein degradation therapy market covered in this report is segmented –

1) By Type: Bavdegalutamide (ARV – 110); Vepdegestrant (ARV – 471); Other Types

2) By Application: Oncology; Neurodegenerative Diseases; Infectious Diseases; Other Applications

3) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes

Subsegment:

1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders; Prostate Cancer Therapy

2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders; Breast Cancer Therapy

What Regions Are Influencing the Dynamics of the Protein Degradation Therapy Market?

North America was the largest region in the protein degradation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Elements Shape the Definition of the Protein Degradation Therapy Market?

Protein degradation therapy is a therapeutic approach that targets the selective degradation of specific proteins within cells. This method involves using small molecules, peptides, or other agents to induce the destruction of proteins that are dysfunctional or contribute to disease. The goal is to reduce or eliminate harmful proteins that are associated with various conditions, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Browse Through More Similar Reports By The Business Research Company:

Home Infusion Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/home-infusion-therapy-global-market-report

CAR-T Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report

Aromatherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/aromatherapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: